CVRX trades 74.2% below Wall Street's consensus target of $10.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CVRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, CVRx, Inc. (CVRX) has a Wall Street consensus price target of $10.00, based on estimates from 7 covering analysts. With the stock currently trading at $5.74, this represents a potential upside of +74.2%. The company has a market capitalization of $152M.
Analyst price targets range from a low of $10.00 to a high of $10.00, representing a 0% spread in expectations. The median target of $10.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CVRX trades at a trailing P/E of -2.8x. Analysts expect EPS to grow +1.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
LIVNLivaNova PLC | $4.6B | $83.58 | $81.43 | -2.6% | Buy | 19.7x | 15 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
LFSTLifeStance Health Group, Inc. | $4.2B | $10.90 | $9.90 | -9.2% | Buy | 80.1x | 11 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
AVNTAvient Corporation | $3.5B | $38.10 | $46.71 | +22.6% | Buy | 12.4x | 20 |
ELMDElectromed, Inc. | $378M | $45.70 | $38.00 | -16.8% | Buy | 37.6x | 5 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
ZBHZimmer Biomet Holdings, Inc. | $17.5B | $89.41 | $96.33 | +7.7% | Hold | 10.5x | 42 |
Quick answers to the most common questions about buying CVRX stock.
The consensus Wall Street price target for CVRX is $10, representing 74.2% upside from the current price of $5.74. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CVRX has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $10 implies 74.2% upside from current levels.
CVRX's current price is $5.74 with a consensus target of $10 (74.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for CVRX, while the most conservative target is $10. The consensus of $10 represents the median expectation. These targets typically reflect 12-month expectations.
CVRX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CVRX stock forecast based on 7 Wall Street analysts shows a consensus price target of $10, with estimates ranging from $10 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CVRX, with a "Buy" consensus rating and $10 price target (74.2% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CVRX analyst price targets range from $10 to $10, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.